局部晚期乳腺癌新辅助化疗

摘要/Abstract

摘要：新辅助化疗是局部晚期乳腺癌综合治疗的常用手段之一，以蒽环类和紫杉烷类为主要化疗药物。近年来，分子靶向药物在显著提高化疗疗效的同时，也为临床提供了更多选择和治疗思路。目前研究较为广泛的靶向治疗药物包括曲妥珠单抗、拉帕替尼、帕妥珠单抗、TDM1和贝伐珠单抗。

刘慧,芮景. 局部晚期乳腺癌新辅助化疗[J]. 国际肿瘤学杂志, 2015, 42(12): 916-919.

Liu Hui, Rui Jing. Neoadjuvant chemotherapy for locally advanced cancer[J]. Journal of International Oncology, 2015, 42(12): 916-919.

［1］ Zardavas D, Piccart M. Neoadjuvant therapy for breast cancer［J］. Annu Rev Med, 2015, 66: 31-48. ［2］ Zaharia M, Gómez H. Neoadjuvant chemotherapy in the treatment of locally advanced breast cancer［J］. Rev Peru Med Exp Salud Publica, 2013, 30(1): 73-78. ［3］ Cardoso F, Costa A, Norton L, et al. ESOESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)［J］. Ann Oncol, 2014, 23(5): 489-502. ［4］ Guha M. PARP inhibitors stumble in breast cancer［J］. Nat Biotechnol, 2011, 29(5): 373-374. ［5］ Silver D, Richardson A, Eklund A, et al. Efficacy of neoadjuvant cisplatin in triplenegative breast cancer［J］. J Clin Oncol, 2010, 28(7): 1145-1153. ［6］ Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant onceperweek paclitaxel followed by dosedense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triplenegative breast cancer: CALGB 40603 (Alliance)［J］. J Clin Oncol, 2015, 33(1): 13-21. ［7］ Pierga JY, Delaloge S, Espié M, et al. A multicenter randomized phase Ⅱ study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients［J］. Breast Cancer Res Treat, 2010, 122(2): 429-473. ［8］ Earl HM, Vallier AL, Hiller L, et al. Effects of the addition of gemcitabine, and paclitaxelfirst sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with highrisk early breast cancer (NeotAnGo): an openlabel, 2×2 factorial randomised phase 3 trial［J］. Lancet Oncol, 2014, 15(2): 201-212. ［9］ Vriens BE, Aarts MJ, de Vries B, et al. Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer［J］. Eur J Cancer, 2013, 49 (15): 3102-3110. ［10］ Eiermann W, Pienkowski T, Crown J, et al. Phase Ⅲ study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2normal, nodepositive breast cancer: BCIRG005 trial［J］. J Clin Oncol, 2011, 29(29): 3877-3884. ［11］ Untch M, Fasching PA, Konecny GE, et al. PREPARE trial: a randomized phase Ⅲ trial comparing preoperative, dosedense, doseintensified chemotherapy with epirubicin, paclitaxel and CMF versus a standarddosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery［J］. Ann Oncol, 2011, 22(9): 1988-1998. ［12］ von Minckwitz G, Blohmer JU, Costa SD, et al. Responseguided neoadjuvant chemotherapy for breast cancer［J］. J Clin Oncol, 2013, 31(29): 3623-3630. ［13］ Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2negative cohort［J］. Lancet, 2010, 375(9712): 377-384. ［14］ Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2positive breast cancer: results from the GeparQuattro study［J］. J Clin Oncol, 2010, 28(12): 2024-2031. ［15］ Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2positive early breast cancer (NeoALTTO): a randomised, openlabel, multicentre, phase 3 trial［J］. Lancet, 2012, 379(9816): 633-640. ［16］ Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2positive operable breast cancer (NSABP protocol B41): an openlabel, randomised phase 3 trial［J］. Lancet Oncol, 2013, 14(12): 1183-1192. ［17］ Rimawi MF, Mayer IA, Forero A, et al. Multicenter phase Ⅱ study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2overexpressing breast cancer: TBCRC 006［J］. J Clin Oncol, 2013, 31(14): 1726-1731. ［18］ Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, doubleblind, placebocontrolled, phase 3 study［J］. Lancet Oncol, 2013, 14(6): 461-471. ［19］ Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2positive breast cancer (NeoSphere): a randomised multicentre, openlabel, phase 2 trial［J］. Lancet Oncol, 2012, 13(1): 25-32. ［20］ Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracyclinecontaining and anthracyclinefree chemotherapy regimens in patients with HER2positive early breast cancer: a randomized phase Ⅱ cardiac safety study (TRYPHAENA)［J］. Ann Oncol , 2013, 24(9): 2278-2284. ［21］ Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2positive advanced breast cancer［J］. N Engl J Med, 2012, 367(19): 1783-1791. ［22］ Pierga JY, Petit T, Delozier T, et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2positive breast cancer (BEVERLY2): an openlabel, singlearm phase 2 study［J］. Lancet Oncol, 2012, 13(4): 375-384. ［23］ Coudert B, Pierga JY, MouretReynier MA, et al. Use of ［(18)F］FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in ［(18)F］FDG PETpredicted nonresponders (AVATAXHER): an openlabel, randomised phase 2 trial［J］. Lancet Oncol, 2014, 5(13): 1493-1502. ［24］ Iqbal J, Bano K, Saeed A, et al. Survival of women with locally advanced breast cancer at a teaching hospital in Lahore［J］. J Pak Med Assoc, 2010, 60(9): 721-725. ［25］ von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes［J］. J Clin Oncol, 2012, 30(15): 1796-1804. ［26］ de Azambuja E, Holmes A, PiccartGebhart M, et al. Lapatinib with trastuzumab for HER2positive early breast cancer (NeoALTTO): survival outcomes of a randomised, openlabel, multicentre, phase 3 trial and their association with pathological complete response［J］. Lancet Oncol, 2014, 15(10): 1137-1146.

[1]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉.乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙.肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙.乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷.中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英.HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰.miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[9]	王文德, 曾德.乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[10]	李青珊, 谢鑫, 张楠, 刘帅.放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏.HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	周婷, 徐少华, 梅林.贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	范珊琳, 汪品秀, 孔飞, 周玉洁, 袁文臻.胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展[J]. 国际肿瘤学杂志, 2023, 50(2): 112-116.
[14]	黎立喜, 张娣, 罗扬, 马飞.PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[15]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦.伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.

Neoadjuvant chemotherapy for locally advanced cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价